Xu Zhang

Xu Zhang

Auto-generated profile, based on publicly available information

Xu Zhang

Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou 510060, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
YZYu-Mo Zhao
Yu-Mo Zhao
YLYing-He Li
Ying-He Li
TCTao Chen
Tao Chen
WZWei-Guang Zhang
Wei-Guang Zhang
LWLin-Hao Wang
Lin-Hao Wang
YHYing-Ying Hu
Ying-Ying Hu

19 November 2021 in Medical Physics
Verified
Journal Article
Closed access
PDF file
LZLipei Zhang
Lipei Zhang
ZXZizheng Xiao
Zizheng Xiao
CZChao Zhou
Chao Zhou
JYJianmin Yuan
Jianmin Yuan
QHQiang He
Qiang He
ZHZhanli Hu
Zhanli Hu

19 December 2017 in Chinese Journal of Cancer
Verified
Journal Article
Open access
PDF file
HPHao Peng
Hao Peng
LLLi-XIa Lu
Li-XIa Lu
LTLing-Long Tang
Ling-Long Tang
WLWen-Fei Li
Wen-Fei Li
YMYan-Ping Mao
Yan-Ping Mao
JMJun Ma
Jun Ma
Little is known about the nature of metastasis to small cervical lymph nodes (SCLNs) in the patients with nasopharyngeal carcinoma (NPC) examined by using 18-fluoro-2-deoxy-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT). The present study aimed to evaluate the diagnostic values of PET/CT in identifying metastasis in SCLNs in NPC patients. Magnetic resonance images (MRI) and PET/CT scans for 470 patients with newly diagnosed, non-distant metastatic NPC were analyzed. Metastatic rates of SCLNs were defined by the positive number of SCLNs on PET/CT scans and total number of SCLNs on MRI scans. Receiver operating characteristic curve was applied to compare PET/CT-determined stage with MRI-determined stage. In total, 2082 SCLNs were identified, with 808 (38.8%) ≥ 5 and < 6 mm in diameter (group A), 526 (25.3%) ≥ 6 and < 7 mm in diameter (group B), 374 (18.0%) ≥ 7 and < 8 mm in diameter (group C), 237 (11.4%) ≥ 8 and < 9 mm in diameter (group D), and 137 (6.5%) ≥ 9 and < 10 mm in diameter (group E). The overall metastatic rates examined by using PET/CT for groups A, B, C, D, and E were 3.5%, 8.0%, 31.3%, 60.0%, and 83.9%, respectively (P < 0.001). In level IV/Vb, the metastatic rate for nodes ≥ 8 mm was 84.6%. PET/CT examination resulted in modification of N category and overall stage for 135 (28.7%) and 46 (9.8%) patients, respectively. The areas under curve of MRI-determined and PET/CT-determined overall stage were 0.659 and 0.704 for predicting overall survival, 0.661 and 0.711 for predicting distant metastasis-free survival, and 0.636 and 0.663 for predicting disease-free survival. PET/CT was more effective than MRI in identifying metastatic SCLNs, and the radiologic diagnostic criteria for metastatic lymph nodes in level IV/Vb should be re-defined.

15 May 2018 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
Linqi ZhangLinqi Zhang
Linqi Zhang
XZXu Zhang
Xu Zhang
QHQiao He
Qiao He
RZRusen Zhang
Rusen Zhang
WFWei Fan
Wei Fan
Extramedullary plasmacytoma (EMP) is a plasma cell malignancy that originates in soft tissues without evidence of systemic spread, and its management differs from other plasma cell neoplasms. The purpose of the present study was to evaluate the role of initial 18F-FDG PET/CT in the management of patients with clinical suspected EMP. 18F-FDG PET/CT scans performed in 21 patients (M/F = 12/9, mean age 51.1 ± 15.3 years) with clear suspicion of EMP from 2006 to 2015 were analysed retrospectively. The detection of new lesions and the change in treatment were evaluated. PET/CT detected new lesions in 38.1% (8/21) of patients with 17 lesions, and lymph nodes were the most common site, accounting for 70.6% (12/17) of all lesions, followed by bone (n = 2), and less frequently, breast (n = 1), lung (n = 1), and stomach (n = 1). These findings resulted in treatment changes in 7 patients with EMP. Among these, 4 patients had major treatment changes and 3 patients had minor changes. Of the 21 patients, progression to MM was observed in 8 patients (8/21, 38.1%). In univariate analysis, tumour size > 4 cm and partial response (PR) after treatment were significant prognostic factors for Progression-free survival (PFS). Our data indicated that 18F-FDG PET/CT is helpful in the detection of additional lesions throughout the body, including lymph node involvement and distant additional lesion, which may have resulted in treatment change.

15 October 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
YLYing-He Li
Ying-He Li
YZYu-Mo Zhao
Yu-Mo Zhao
YJYong-Luo Jiang
Yong-Luo Jiang
STSi Tang
Si Tang
MCMei-Ting Chen
Mei-Ting Chen
XZXu Zhang
Xu Zhang

25 November 2022 in Academic Radiology
Verified
Journal Article
Closed access
YCYingpu Cui
Yingpu Cui
YJYongluo Jiang
Yongluo Jiang
XDXi Deng
Xi Deng
WLWen Long
Wen Long
BLBaocong Liu
Baocong Liu
XZXu Zhang
Xu Zhang